Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Company Overview and Strategic Pillars
TECH logo

Bio-Techne Achieves 9% Organic Sales Growth in Q2 Amid Biopharma Recovery

TECH10-QFiling Date: 2/6/2025
Bio-Techne Corporation
Description

What this story covers

Bio-Techne reported Q2 fiscal 2025 net sales of $297M, up 9% organically, driven by diagnostics and spatial biology. Adjusted margins improved to 70.5%, with strong cash flow of $148M from operations. Restructuring optimizes efficiency, while investments in Spear Bio and Wilson Wolf target cell therapy growth. No major risk changes; focus on shareholder returns via buybacks and dividends.

Story snapshot

CompanyBio-Techne Corporation
TickerTECH
VariantStandard detailed
Duration14:18
Filing type10-Q
PeriodQ2 2025
IndustryHealthcare & Pharmaceuticals
Accession0001558370-25-000689

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in